Additional bipolar indication for Seroquel

29 October 2009

Seroquel and Seroquel XL (quetiapine) have been approved for the treatment of major depressive episodes in adults with bipolar disorder, in addition to the products' existing indications for schizophrenia and manic episodes. The new indication, for which the maximum daily dose is 600mg, carries a black triangle to indicate that all adverse events should
be reported.

View Seroquel drug record

Further information: AstraZeneca

To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...